Ryan Maynard

Track

Insider profile

Currently holds a position at Iovance Biotherapeutics Inc

Performance

Overall performance
3.3
Performance over holding periods
4.2
30 days 90 days 120 days
Average return 25% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
2 50% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Performance for realised trades
4.4
Average return 49%
Success rate 73%
Average holding period 220
Transactions 28
Ranking by realised performance

Positions

Position Company Period
Independent Director Iovance Biotherapeutics Inc Feb. 16, 2015 -
Chief Financial Officer and Executive Vice President Rigel Pharmaceuticals Inc March 1, 2010 - Dec. 31, 2017
Ryan Maynard's trades of Iovance Biotherapeutics Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Planned sale
Price
156.37
Quantity 82,999 +36.8%
Value US$4,023,746
Transaction date
Purchase
Price
6.75
Quantity 7,500 +inf%
Value US$50,588
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2024-11-14 2024-11-12
S Sale
42,179 +13.4%
316.76
US$3,894,052 		42,179 +13.4% 316.76 US$3,894,052
2024-11-12 2024-11-12
PrS Proposed sale
13,364
458.84
US$1,984,840 		13,364 458.84 US$1,984,840
2024-02-12 2023-02-08
PlS Planned sale
82,999 +36.8%
156.37
US$4,023,746 		82,999 +36.8% 156.37 US$4,023,746
2022-06-02 2022-05-31
B Purchase
7,500 +inf%
6.75
US$50,588 		7,500 +inf% 6.75 US$50,588